Join
Live feed
·
PRReleasevia Quantisnow
Immutep Limited logo

Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases

ByQuantisnow·Wall Street's wire, on your screen.
IMMP· Immutep Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IMMP (Immutep Limited) and more on Quantisnow.